Octagon Capital Advisors LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001839435

What is a 13F filing? Who files one and when · What 13F filings can't tell you

MidFocusedHealth TiltHigh Turnover how tags are computed

Q2 2026 · 27 positions · Total reported value $1.11B · Top-10 concentration 78.5% · Updated 2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

Turnover: 65.5% · 2 new · 14 cut · 3 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -23.3% · vs SPY -25.4% · Prev Value $1.11B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -9.9% · vs SPY -12.0% · Latest Value $750.61M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2026 13F filing, Octagon Capital Advisors LP disclosed 27 equity positions with a combined reported value of $1.11B. The filing implies a focused portfolio: its ten largest positions account for 78.5% of reported value. HoldingsHub classifies the profile as Mid / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2026 were DNTH ($179.53M), DFTX ($138.77M), ABVX ($132.33M). By sector, the heaviest allocations are Health Care 99.2%, Other 0.8%. Versus the prior quarter, allocation shifted toward Health Care (+8.8pp) and away from Other (-8.8pp).

Versus the prior quarter, Octagon Capital Advisors LP opened 2 new positions, trimmed 14 and fully exited 3, a turnover rate of 65.5% of positions. The portfolio's overlap with the prior quarter was 65% of names.

The largest new positions opened in Q2 2026 were ERAS ($22.99M), SMMT ($18.21M), ANL ($10.75M).

Of the 3 positions fully exited versus the prior quarter, the largest were CNTA ($29.79M), KALV ($29.19M), TERN ($27.94M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2026)

  • ERAS ERASCA INC · $22.99M
  • SMMT SUMMIT THERAPEUTICS INC · $18.21M
  • ANL ADLAI NORTYE GROUP LTD · $10.75M
  • FTH FAETH THERAPEUTICS INC · $9.03M
  • GYRE GYRE THERAPEUTICS INC · $6.29M

Fully Exited (vs previous quarter)

  • CNTA CENTESSA PHARMACEUTICALS PLC · prev qtr: $29.79M
  • KALV KALVISTA PHARMACEUTICALS INC · prev qtr: $29.19M
  • TERN TERNS PHARMACEUTICALS INC · prev qtr: $27.94M
  • BBOT BRIDGEBIO ONCOLOGY THERAPEUT · prev qtr: $6.44M
  • LXEO LEXEO THERAPEUTICS INC · prev qtr: $6.31M
  • CATX PERSPECTIVE THERAPEUTICS INC · prev qtr: $3.30M
  • EVMN EVOMMUNE INC · prev qtr: $3.30M

Insider Transactions (Form 4)

Latest Octagon Capital Advisors LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Octagon Capital Advisors LP is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 26 US equity positions with a combined value of $750.61M. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-118554 (status: Approved), registered 2020-04-27
  • Regulatory AUM (Form ADV): $1.18B as of 2026-03-20
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 4 private funds, of which 1 hedge funds
  • Website: octagoninvestments.com

Portfolio Structure

  • 26 positions · $750.61M reported value (Q3 2026)
  • Top 10 holdings = 82.5% of reported value
  • Largest position: DNTH (DIANTHUS THERAPEUTICS INC) at 19.8%
  • Average position size: $28.87M

Sector Tilt

  • Health Care 99.6%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 2 new, 1 added, 14 reduced, 3 exited
  • 9 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to be maintaining a cautious yet proactive stance. It has selectively increased positions in some healthcare stocks and reduced others, indicating a focus on potential growth opportunities within the healthcare sector, though with a preference for certain companies over others. 2. Key Moves: - Added: Definium Therapeutics (DFTX) by 20.9% and Arrivant Biopharma (AVBP) by 0.0% (though not specified, it seems to be a hold in terms of shares). Taysha Gene Therapies (TSHA) was added significantly, showing confidence in their growth prospects. - Reduced: Dianthus Therapeutics (DNTH) by 5.4%, indicating a less favorable view of the company or sector. Kymera Therapeutics (KYMR) was reduced by 27.1%, suggesting potential concerns about the company's prospects. 3. Portfolio Structure: - The fund seems to have a blend of active and passive strategies, with some holdings held constant and others adjusted. - Sector Bias: The portfolio is heavily skewed towards the healthcare sector, reflecting a strong interest in this area. - Risk Appetite: The risk appetite seems balanced, with the addition of new positions in growth-oriented companies like TSHA, but also a reduction in positions that may have become less attractive. 4. Per-Holding One-Liner: - DNTH: Dianthus Therapeutics, a clinical-stage biotechnology company focused on developing novel therapies for rare and orphan diseases. - DFTX: Definium Therapeutics, a biotechnology company focused on the development of next-generation therapies for cancer and rare genetic diseases. - ABVX: Abivax, a biopharmaceutical company focused on developing novel therapies for metabolic diseases and chronic inflammation. - COGT: Cogent Biosciences, a biotechnology company focused on developing novel therapies for cancer and other diseases. - ALMS: Alumis, a biopharmaceutical company focused on the development of therapies for rare and orphan diseases. - AVBP: Arrivant Biopharma, a biotechnology company focused on developing novel therapies for cancer and other diseases. - TSHA: Taysha Gene Therapies, a company developing gene therapies for rare genetic disorders. - BIOA: BioAge Labs, a biotechnology company focused on aging and longevity research. - MIRM: Mirum Pharmaceuticals, a biopharmaceutical company focused on the development of therapies for rare genetic diseases. - KYMR: Kymera Therapeutics, a company developing novel therapies for cancer and other diseases. (unverified) 5. One-Sentence Style Summary: Octagon Capital Advisors LP maintained a cautious approach in Q2 2026, selectively adding and reducing healthcare holdings, with a focus on growth-oriented companies in the sector while adjusting its risk exposure.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Health Care 99.2%
Other 0.8%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 1.84M $179.53M 16.14%
16.14%
Reduce
2 2.95M $138.77M 12.47%
12.47%
Add
3 993.00K $132.33M 11.89%
11.89%
Add
4 2.35M $90.94M 8.18%
8.18%
Hold
5 2.83M $79.66M 7.16%
7.16%
Hold
6 1.97M $68.47M 6.16%
6.16%
Hold
7 9.69M $66.01M 5.93%
5.93%
Add
8 1.75M $42.84M 3.85%
3.85%
Hold
9 338.90K $39.68M 3.57%
3.57%
Hold
10 310.00K $35.55M 3.19%
3.19%
Reduce
11 960.85K $30.97M 2.78%
2.78%
Hold
12 490.00K $29.58M 2.66%
2.66%
Hold
13 1.25M $22.99M 2.07%
2.07%
New
14 10.28M $21.48M 1.93%
1.93%
Hold
15 2.08M $20.38M 1.83%
1.83%
Reduce
16 270.00K $19.75M 1.77%
1.77%
Hold
17 1.25M $18.21M 1.64%
1.64%
New
18 456.72K $15.79M 1.42%
1.42%
Add
19 934.72K $10.75M 0.97%
0.97%
New
20 1.35M $10.61M 0.95%
0.95%
Reduce
21 574.20K $9.42M 0.85%
0.85%
Hold
22 361.01K $9.03M 0.81%
0.81%
New
23 954.42K $6.29M 0.56%
0.56%
New
24 315.00K $5.87M 0.53%
0.53%
Reduce
25 1.00M $4.69M 0.42%
0.42%
Hold
26 3.05M $1.69M 0.15%
0.15%
Reduce
27 7.75M $1.28M 0.12%
0.12%
Hold

FAQ

What did Octagon Capital Advisors LP buy in 2026-Q2?

In its 2026-Q2 13F filing, Octagon Capital Advisors LP reported 27 equity positions worth $1.11B in aggregate; its largest disclosed positions were DNTH ($179.53M), DFTX ($138.77M), ABVX ($132.33M).

How large is Octagon Capital Advisors LP's portfolio?

Octagon Capital Advisors LP reported $1.11B of long equity holdings across 27 positions as of 2026-Q2. Top-10 holdings account for 78.5% of reported value.

What is Octagon Capital Advisors LP's investment style?

HoldingsHub classifies the portfolio as Mid / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/octagon-capital-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →